Compare OSK & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSK | ABVX |
|---|---|---|
| Founded | 1917 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.2B |
| IPO Year | N/A | N/A |
| Metric | OSK | ABVX |
|---|---|---|
| Price | $172.22 | $117.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $156.71 | $130.09 |
| AVG Volume (30 Days) | 936.3K | ★ 1.5M |
| Earning Date | 01-29-2026 | 03-23-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.02 | N/A |
| Revenue | ★ $10,422,300,000.00 | $6,231,374.00 |
| Revenue This Year | $5.91 | $6.80 |
| Revenue Next Year | $6.89 | N/A |
| P/E Ratio | $16.32 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $76.82 | $4.77 |
| 52 Week High | $169.62 | $148.83 |
| Indicator | OSK | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 68.43 | N/A |
| Support Level | $136.55 | N/A |
| Resistance Level | $169.62 | N/A |
| Average True Range (ATR) | 6.30 | 0.00 |
| MACD | 0.93 | 0.00 |
| Stochastic Oscillator | 87.63 | 0.00 |
Oshkosh is a leading maker of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, including postal, firefighting, refuse/recycling collection, aviation, and construction. It is typically the market share leader or No. 2 player in North America, or even the global leader in the case of its JLG aerial work platform business. The transport segment is a leading provider of light trucks to the military and vehicles to the Postal Service. The vocational segment, featuring brands such as Pierce, AeroTech, and Volterra, offers purpose-built vehicles and equipment to municipalities. The company reports three segments—Access equipment (49% of revenue), Vocational (31%), and Transport (20%) on 2024 revenue of $10.7 billion.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.